pranlukast

cysteinyl leukotriene receptor antagonist · Antiasthmatic agent (Leukotriene pathway inhibitor.) (p818, p824, p826). It is a selective CysLTr1 antagonist (p818, p824), and it prevents activation of CysLTr1. (p818, Figure 41-2 legend). Used in the treatment of mild-to-moderate asthma. (p818, p824). It is also the mainstay of treatment for AERD (aspirin-exacerbated respiratory disease). (p824). (from table) Therapeutic Uses: Asthma, AERD. Clinical Pharmacology: CysLTr1 antagonist. (p826). I have extracted all relevant information for pranlukast based on the provided text. The mechanism of action is accurately described as a selective CysLTr1 antagonist, and its indications for asthma and AERD are clearly stated. I've also included the page references for traceability. I noticed the classification of this drug is 'Cysteinyl Leukotriene Receptor Antagonists' (p826), and its function is to block the CysLTr1 receptor (p818), which is consistent with the drugClass and mechanism I provided. The instructions emphasize direct extraction from the text, which I followed. (p818). The